Navigating Pain Management during the Opioid Epidemic: Focus Group Findings

Similar documents
PDMP Tools to Identify Red Flag Situations

Defining the Role of the Pharmacist in Combatting the Opioid Epidemic

IMPLEMENTATION OF A SHARED MEDICAL APPOINTMENT FOR OPIOID OVERDOSE EDUCATION AND NALOXONE KIT TRAINING FOR VETERANS Kristin A. Tallman, Pharm.

Running Head: PICOT-D ASSIGNMENT 1. NURS 610: PICOT-D Assignment. Peggie L. Powell. VCU School of Nursing DNP Program

Opioid Epidemic as it Relates to Counties

Teaming Up for Safer Pain Management: Strategies for Effective Collaboration

Report to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program

Jerry Cochran, MSW, PhD University of Utah School of Medicine Department of Internal Medicine Department of Psychiatry

The Impact of the U.S. Drug Enforcement Agency Schedule Changes for Hydrocodone and Tramadol on California Prescriptions Patterns

Ontario s Narcotics Strategy

Chronic Pain: Decreasing Dependence on Opioids

Aetna s Initiative on the Opioid Epidemic

Resources Encouraging Safe Prescription Opioid & Naloxone Dispensing: Results from the RESPOND Study

PHARMACY Section 9. Overview. Preferred Drug List. Additions and Exceptions to the Preferred Drug List

Applying Population Health Management to Opiate Prescription Medication Misuse

Using PDMP Data to Guide Interventions with Possible At-Risk Prescribers

Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices

New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS

Addressing the Opioid Epidemic in Tennessee

ScO.S. Academic Detailing for Safer Prescribing

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists

Why pay for Continuing Education when you can get it for FREE!?

September 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic

Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy

Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch

TITLE AUTHORS. Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy

Reviewing patients using opioid medicines long-term for non-cancer pain

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

What is drug diversion?

The 86 th Texas Legislature s Policy Response to Opioids Prepared by the Texas Orthopaedic Association

Managing Risks Associated with Doctor Shopping and Other Drug-Seeking Behaviors

Understanding and Combating the Heroin Epidemic

Wisconsin Statewide Substance Abuse Prevention Training Wisconsin Dells June 12, 2015

Shannon Whitman Program Administrator Advancing Use of the MN PMP

Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx

9/17/2018. Capstone Committee Chair Dr. Brenda Cassidy, DNP, RN, PCNP-PC Assistant Professor Health Promotion and Development

ROOM project Addressing the Opioid Epidemic in the U.P. Presented by; Kevin L. Piggott, MD, MPH May 21, 2018

Slide 1. Slide 2. Slide 3

Best Practices and Foundation Forum. Fred Wells Brason II

Opioid Guardianship Project: Combating the Opioid Crisis Sarah Derr, PharmD Meg Nugent, MHA, RN Iowa Healthcare Collaborative

Provider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting

Presentation Objectives

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Prescription Opioid Policies (22 March 2016)

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

Opioid epidemic and PEHP

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018

Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks

Safe States Alliance 2018 Innovative Initiatives Finalist Summaries for Review

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

Oregon s PDMP: An epidemiological assist tool

6/6/2017. First Do No Harm SECTION 1 THE OPIOID CRISIS. Implementing an Opioid Stewardship Program in a HealthCare System OBJECTIVES

Risk Reduction Strategies in Pain Management

Scope of the Opiate Problem 6/5/18. Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond. Overview.

Addressing Prescription Drug Abuse. Allan Coukell Senior Director, Drugs and Medical Devices The Pew Charitable Trust

Opioids: The Cause of, and Solution

Safe Medication Practices

United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America

Teaching Objectives Describe the balance a that must be sought in the treatment of pain and the prevention of drug diversion. Discuss regulatory polic

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

DISCLAIMER CONTRIBUTORS

WORKING UPSTREAM TO COMBAT THE OPIOID CRISIS

Naloxone and Combating the Opioid Epidemic

BUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES

North Dakota Board of Pharmacy

Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic

Potential Solutions to Epidemic Substance Abuse in US and Europe

Pharmaceutical Misuse and its Challenges: Opioid Use in Ontario. Ontario Harm Reduction Conference Tara Gomes Tuesday January 31, 2012

See Important Reminder at the end of this policy for important regulatory and legal information.

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

The Opioid Epidemic and How It is Impacting the Workplace. July 24, 2018

New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers

Maximizing Safety and Efficacy in Methadone Dosing Among Hospice Patients. Introduction

The Opioid Epidemic and PerformRx s Approach to Address It: A Collaborative Model with PBM, Payor and Behavioral Health

Controlled Substances: A survey of tools and resources required by hospital pharmacists

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good

Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy

DURATION LIMIT CRITERIA ACETAMINOPHEN/ASPIRIN/IBUPROFEN CONTAINING OPIOID ANALGESICS (BRAND AND GENERIC) (acetaminophen and benzhydrocodone)

OPIOID & PAIN MANAGEMENT CONFERENCE

Liability, Informed Consent, and Risk Management 15 Thoughts for Pain Management Physicians

REAL TIME MONITORING OF PRESCRIPTION MEDICINES BEING A HEALTHY STATE

Managed Care Pushes for Safer Opioid Oversight

Confronting The Opioid Epidemic.

Opioid Use Disorder. A Telligen White Paper. Katy Brown, PharmD Clinical Pharmacy Specialist

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

Opioid Focus Group Summaries

Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary

WHAT YOU NEED TO KNOW TO ABOUT AB 474

Stories to Promote Information Using Narrative (SPIN) Trial

Prescription Drug Monitoring Programs and Other State-Level Strategies

MEDICAL ASSISTANCE BULLETIN

Using CURES to combat prescription drug abuse/misuse

Prescription Drugs: Issues in Treatment, Supervision and Case Management

The Role of the PDMP: Foundational Knowledge and Best Practices

COLLEGE OF PHYSICIANS AND SURGEONS OF NOVA SCOTIA DECISION OF INVESTIGATION COMMITTEE A. Mr. Kevin Lynch, Manager, PMP XXXXXXXXXXX

Transcription:

Navigating Pain Management during the Opioid Epidemic: Focus Group Findings David Cameron Oregon Health & Science University Department of Family Medicine, Portland, OR Funding received from AHRQ (5R18HS024227-02)

Overview Purpose Current norms and practices Focus group findings Conclusions RESPOND toolkit

Quick Poll: Should pharmacists be involved in chronic pain management? Should pharmacists be involved in pain medication safety?

Corresponding Responsibility Cash payment Distant prescriber High-risk combinations Early refills Multiple pharmacies

Latest Guidelines for Pharmacists Corresponding Responsibility Monitor for Red Flags Restrict high-risk medications Inappropriate quantity Early refills Multiple pharmacies

Purpose Understand the situation from multiple perspectives Collect patient stories Reduce ambiguity

Focus Groups Pharmacists: 2 groups of 7-12 Patients: 3 groups of 4-8

Focus Group Findings PHARMACISTS felt discomfort filling high-risk prescriptions PATIENTS were concerned about pharmacists interfering PHARMACISTS wanted to respect the doctor-patient relationship PATIENTS were concerned about delays PHARMACISTS wanted to ensure patient safety PATIENTS felt judgment from healthcare professionals

Pharmacists felt discomfort filling high-risk opioid prescriptions

Patients were concerned about pharmacists interfering with their doctor s treatment plan

Patients were concerned about delays getting their medications

Pharmacists wanted to respect the doctor-patient relationship

Pharmacists wanted to ensure patient safety

Patients felt judgment from healthcare professionals and reduced trust in the medical system

Quick Poll: Who has experienced stigma or judgment due to chronic pain or taking pain medication? Who feels they are included in conversations about their pain medications?

Patient Strategies: One Doctor

Patient Strategies: Self-Advocacy

Patient Strategies: Peer Support

Quick Poll: Who has used one of these strategies?

Conclusions Patients should be the central feature in new pain management models

Conclusions Improved training for healthcare professionals

Based on Your Feedback 1. Patients are consulted about medication concerns before the pharmacist contacts the doctor and/or cancels a prescription. 2. Conversations about pain medication are judgment free, and geared toward safety and health. 3. Pharmacists ask permission before offering unsolicited information about pain medication safety

References Fleming ML, Barner JC, Brown CM, Shepherd MD, Strassels S, Novak S. Using the theory of planned behavior to examine pharmacists intention to utilize a prescription drug monitoring program database. Research in Social and Administrative Pharmacy. 2014;10:285-96. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65(1):1 49. American Pharmacists Association. Pharmacists role in addressing opioid abuse, addiction, and diversion. Journal of the American Pharmacists Association. 2014;54(1):e5-15. Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice. Journal of Pharmacy Practice. 2014;1 9. Marlowe KF, Geiler R. Pharmacist s role in dispensing opioids for acute and chronic pain. J Pharm Pract. 2012;25(5):497 502. Epub 2011 Apr 5. Cochran G, Field C, Lawson K, Erickson C. Pharmacists knowledge, attitudes, and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists. Journal of Pharmaceutical Health Services Research. 2013;4:71-9. Cobaugh D J, Gainor C, Gaston C L, Kwong TC, Magnani B, Mcpherson M Lynn, et al. The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems. American Journal of Health-System Pharmacy. 2014;71:1539 54.

Thank you! We appreciate the valuable contributions from all patients and pharmacists who participated in this study. Thank you, Michelle Marikos, the Moving Through Chronic Pain Community Forum, and the Southern Oregon community for allowing us to share our work.